Skip to the page

Data / Drug companies / Patheon Manufacturing Services LLC

Patheon Manufacturing Services LLC: 92 products in the FDA NDC directory, labeler code 63552

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Patheon Manufacturing Services LLC (labeler code 63552) lists 92 products in the FDA National Drug Code Directory. By type: 90 drugs for further processing, 2 vaccines. Its main marketing category is drugs for further processing. The newest product started marketing on September 4, 2026.

The request: Watch Patheon Manufacturing Services LLC (FDA labeler code 63552): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
63552
Products in commercial distribution
92
Packages
106
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Controlled substance products
Schedule II 11, Schedule IV 2
Started marketing in the last 12 months
4
Products with a marketing end date set
5
Earliest marketing start
January 10, 1967
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing9198.9%
Biologics (BLA)11.1%

Products by type

TypeProductsShare
Drugs for further processing9097.8%
Vaccines22.2%

Dosage forms

Dosage formProductsShare
Injection2122.8%
Tablet1516.3%
Injection, powder, lyophilized, for solution1415.2%
Injection, solution1010.9%
Capsule88.7%
Solution44.3%
Tablet, extended release44.3%
Tablet, film coated33.3%
Injection, solution, concentrate22.2%
Tablet, film coated, extended release22.2%
Injection, powder, for solution22.2%
Injection, suspension22.2%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Camizestrant63552-290Tablet, film coatedDrugs for further processingSeptember 4, 2026
Water63552-287InjectionDrugs for further processingJanuary 14, 2026
Water63552-286InjectionDrugs for further processingJanuary 14, 2026
Ephedrine sulfate63552-282InjectionDrugs for further processingDecember 23, 2025
Ixekizumab63552-280Injection, solutionDrugs for further processingOctober 23, 2025
Plerixafor63552-725Injection, solutionDrugs for further processingSeptember 1, 2025
Nirsevimab63552-724InjectionDrugs for further processingSeptember 1, 2025
Nirsevimab63552-723InjectionDrugs for further processingSeptember 1, 2025
Fluzone high dose northern hemisphere63552-722Injection, suspensionBiologics (BLA)September 1, 2025
Clesrovimab63552-269Injection, solutionDrugs for further processingJune 9, 2025
.alpha.1-proteinase inhibitor human63552-213InjectionDrugs for further processingJanuary 17, 2025
.alpha.1-proteinase inhibitor human63552-210InjectionDrugs for further processingJanuary 17, 2025
Human papillomavirus quadrivalent (types 6, 11, 16, and 18)63552-212Injection, suspensionDrugs for further processingDecember 23, 2024
Foscarbidopa/foslevodopa63552-215InjectionDrugs for further processingOctober 17, 2024
Aflibercept-jbvf63552-281InjectionDrugs for further processingMay 20, 2024
Naxitamab63552-209InjectionDrugs for further processingNovember 7, 2023
Asparaginase erwinia chrysanthemi (recombinant)-rywn63552-285InjectionDrugs for further processingOctober 31, 2023
Talquetamab63552-199InjectionDrugs for further processingAugust 9, 2023
Nirsevimab63552-208InjectionDrugs for further processingJuly 18, 2023
Nirsevimab63552-207InjectionDrugs for further processingJuly 18, 2023
Teclistamab63552-198InjectionDrugs for further processingOctober 25, 2022
Teclistamab63552-197InjectionDrugs for further processingOctober 25, 2022
Trastuzumab-anns63552-270Injection, powder, lyophilized, for solutionDrugs for further processingAugust 2, 2022
Tecovirimat63552-193Injection, solution, concentrateDrugs for further processingMay 31, 2022
Semaglutide63552-206Injection, solutionDrugs for further processingJune 5, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.